Key result
Enoxaparin use for VTE prophylaxis following total hip or knee arthroplasty was associated with a lower rate of any postoperative bleeding compared with rivaroxaban.
Why the study?
Does enoxaparin reduce postoperative bleeding compared to rivaroxaban in patients undergoing total hip or knee arthroplasty?
Cohort
Does enoxaparin reduce postoperative bleeding compared to rivaroxaban in patients undergoing total hip or knee arthroplasty?
In patients undergoing total hip or knee arthroplasty, enoxaparin for VTE prophylaxis was associated with significantly lower rates of postoperative bleeding compared to rivaroxaban.
Answers are grounded in this paper and cite their sources.
May warrant caution with rivaroxaban for VTE prophylaxis post-arthroplasty; leaves open whether bleeding differences persist in prospective trials.
BACKGROUND: The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg daily with commonly used doses of enoxaparin and demonstrated similar rates of VTE and bleeding. OBJECTIVE: To evaluate bleeding events between patients who received enoxaparin or rivaroxaban for prevention of venous thromboembolism (VTE) following total hip arthroplasty (THA) or total knee arthroplasty (TKA). METHODS: Retrospective cohort that compared patients undergoing THA and TKA who received enoxaparin (enoxaparin) with those who received rivaroxaban (rivaroxaban) and also with those who received enoxaparin in the RECORD 1 to 4 trials (enoxaparin RECORD). The primary outcome was any postoperative bleeding, defined as a composite of major and clinically relevant nonmajor bleeding based on the definitions in the RECORD 1 to 4 trials. RESULTS: There was a lower rate of any postoperative bleeding (2.2% vs 6.8%, P = 0.004) in patients who received enoxaparin compared with rivaroxaban, and bleeding rates between the enoxaparin group and the enoxaparin RECORD groups were similar (2.2% vs 2.5%, P = 0.085). Major bleeding in the enoxaparin group (0.2%) was not significantly different from that in the rivaroxaban group (1.4%, P = 0.12) or the RECORD group (0.2%, P = 0.93). Clinically relevant nonmajor bleeding was also lower in the enoxaparin group compared with the rivaroxaban group (2.0% vs 5.5%, P = 0.012). CONCLUSIONS: The use of enoxaparin for VTE prophylaxis following THA and TKA was associated with a lower rate of the primary outcome (any postoperative bleeding) compared with the use of rivaroxaban in a similar cohort of patients.
No takes yet. Share an insight, caveat, or question.
Ricket et al. (2016) conducted a cohort in Venous thromboembolism prophylaxis following total hip or knee arthroplasty. Enoxaparin vs. Rivaroxaban was evaluated on Any postoperative bleeding (composite of major and clinically relevant nonmajor bleeding) (p=0.004). Enoxaparin use for VTE prophylaxis following total hip or knee arthroplasty was associated with a lower rate of any postoperative bleeding compared with rivaroxaban.
Synapse has enriched 10 related papers. Consider them for comparative context: